Biotech Holdings Ltd. is primarily engaged in the development and distribution of its Type II Diabetes drug, known as DIAB II (also known as Sucanon and Glucanin). The operations of the Company's subsidiary for the development, manufacture and distribution of lotions and creams were discontinued during the fiscal year ended March 31, 2003 (fiscal 2003). The pharmaceutical business is divided into the two regions: China and other Asia Countries, which are defined as Indonesia, Philippines, Malaysia, Kampuchia (Cambodia), Thailand, Laos, China, Mongolia, Japan, North Korea, South Korea, Vietnam, Hong Kong, Macao and Singapore, and All other countries. DIAB II is a synthesized molecule that has significant hypoglycemic effect in non-insulin dependent diabetes mellitus (NIDDM) patients.